World Health Organization. Ebola situation report . 11 may 2016. 2016. http://apps.who.int/gho/data/view.ebola-sitrep.ebola-summary-20160511?lang=en. Accessed 7 May 2017.
Garske T, Cori A, Ariyarajah A, Blake IM, Dorigatti I, Eckmanns T, et al. Heterogeneities in the case fatality ratio in the west African Ebola outbreak 2013–2016. Philos Trans R Soc London B Biol Sci. 2017; doi: 10.1098/rstb.2016.0308.
Coltart CEM, Lindsey B, Ghinai I, Johnson AM, Heymann DL. The Ebola outbreak, 2013-2016: old lessons for new epidemics. Philos Trans R Soc B. 2017:372. doi: 10.1098/rstb.2016.0297.
U.S. Food and Drug Administration. Center for Drug Evaluation and Research. In: Guideline for the study and evaluation of gender differences in the clinical evaluation of drugs. Washington: Federal Register; 1993. 58(139):39406-16.
Sherman LA, Temple R, Merkatz RB. Women in clinical trials: an FDA perspective. Science (80- ). 1995; doi:10.1126/science.7638593.
Merkatz RB, Temple R, Sobel S, Kessler DA. Working group on women in clinical trials. Women in clinical trials of new drugs: a change in Food and Drug Administration policy. N Engl J Med. 1993;9:292–6.
Merkatz RB, Junod SW. Historical background of changes in FDA policy on the study and evaluation of drugs in women. Acad Med. 1994;69:703–7.
Merkatz RB. Inclusion of women in clinical trials: a historical overview of scientific, ethical, and legal issues. J Obstet Gynocology Neonatal Nurs. 1998;27:78–84.
Shields KE, Lyerly AD. Exclusion of pregnant women from industry-sponsored clinical trials. Obstet Gynecol. 2013;122:1077–81.
Adam MP, Polifka JE, Friedman JM. Evolving knowledge of the teratogenicity of medications in human pregnancy. Am J Med Genet Part C Semin Med Genet. 2011;157:175–82.
Merkatz R, Temple R, Sobel S, Feiden K, Kessler DA. Trials WG on W in C. Women in clinical trials of new drugs: a change in Food and Drug Administration policy. N Engl J Med. 1993;329:292–6.
Lyerly AD, Little MO, Faden RR. Reframing the framework: toward fair inclusion of pregnant women as participants in research. Am J Bioeth. 2011;11:50–2.
Cragan JD. Medication use during pregnancy. BMJ. 2014;349 doi: 10.1136/bmj.g5252.
Holmes LB. Human teratogens: Update 2010. Birth Defects Res Part A - Clin Mol Teratol. 2011;91:1–7.
Macklin R. Enrolling pregnant women in biomedical research. Lancet. 2010;375:632–3.
Alirol E, Kuesel AC, Guraiib MM, de la Fuente-Núñez V, Saxena A, Gomes MF. Ethics review of studies during public health emergencies - the experience of the WHO ethics review committee during the Ebola virus disease epidemic. BMC Med Ethics. 2017;18
Mupapa K, Mukundu W, Bwaka MA, Kipasa M, De Roo A, Kuvula K, et al. Ebola hemorrhagic fever and pregnancy. JID. 1999;179 Suppl 1:22–3.
Report of an International Commission. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ. 1978;56:271–93.
Jamieson DJ, Uyeki TM, Callaghan WM, Meaney-Delman D, Rasmussen SA. What obstetrician–gynecologists should know about Ebola. Obstet Gynecol. 2014;124:1005–10.
Francesconi P, Yoti Z, Declich S, Onek PA, Fabiani M, Olango J, et al. Ebola hemorrhagic fever transmission and risk factors of contacts, Uganda. Emerg Infect Dis. 2003;9:1430–7.
Nelson JM, Griese SE, Goodman AB, Peacock G. Live neonates born to mothers with Ebola virus disease: a review of the literature. J Perinatol. 2016;36:411–4.
World Health Organization. Potential Ebola therapies and vaccines: interim guidance. 2014. http://apps.who.int/iris/handle/10665/137590. Accessed 15 Dec 2014.
Bausch DG, Sprecher AG, Jeffs B, Boumandouki P. Treatment of Marburg and Ebola hemorrhagic fevers: a strategy for testing new drugs and vaccines under outbreak conditions. Antivir Res. 2008;78:150–61.
Jones SM, Feldmann H, Ströher U, Geisbert JB, Fernando L, Grolla A, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med. 2005;11:786–90.
Qiu X, Fernando L, Alimonti JB, Melito PL, Feldmann F, Dick D, et al. Mucosal immunization of cynomolgus macaques with the VSVΔG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS One. 2009; doi: 10.1371/journal.pone.0005547.
Geisbert TW, Daddario-Dicaprio KM, Lewis MG, Geisbert JB, Grolla A, Leung A, et al. Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog. 2008;4:e1000225.
Kobinger GP, Feldmann H, Zhi Y, Schumer G, Gao G, Feldmann F, et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology. 2006;346:394–401.
Geisbert TW, Bailey M, Hensley L, Asiedu C, Geisbert J, Stanley D, et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol. 2011;85:4222–33.
Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup RA, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol. 2006;13:1267–77.
van Griensven J, Edwards T, Baize S. Efficacy of convalescent plasma in relation to dose of Ebola virus antibodies. N Engl J Med. 2016; doi: 10.1056/NEJMc1609116.
Schopper D, Ravinetto R, Schwartz L, Kamaara E, Sheel S, Segelid MJ, et al. Research ethics governance in times of Ebola. Public Health Ethics. 2016; doi: 10.1093/phe/phw039.
Dunning J, Kennedy SB, Antierens A, Whitehead J, Ciglenecki I, Carson G, et al. Experimental treatment of ebola virus disease with brincidofovir. PLoS One. 2016;11:1–10.
Council for International Organizations of Medical Sciences (CIOMS). International ethical guidelines for biomedical research involving human subjects. CIOMS. https://cioms.ch/shop/product/international-ethical-guidelines-for-health-related-research-involvinginvolvinghumans/. Accessed 14 Aug 2014
Ethical considerations for use of unregistered interventions for Ebola virus disease - Report of an advisory pannel to WHO. 2014.
Mastroianni AC, Faden R, Federman D. Women and Health Research: ethical and legal issues of including women in clinical studies, volume I. Washington, DC: National Academy Press; 1994.
Little MO, Lyerly AD, Faden RR. Pregnant women & medical research: a moral imperative. Bioethica Forum. 2009;2:60–5.
Blehar MC, Spong C, Grady C, Goldkind SF, Sahin L, Clayton JA. Enrolling pregnant women: issues in clinical research. Womens Heal Issues. 2013; doi: 10.1016/j.whi.2012.10.003.
Sissoko D, Laouenan C, Folkesson E, Lebing AM, Malme K, Manfrin E, et al. Experimental treatment with Favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of- concept trial in Guinea. PLoS Med. 2016;13 doi: 10.1371/journal.pmed.1001967.
van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S, et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med. 2016; doi: 10.1056/NEJMoa1511812.
Huttner A, Dayer JA, Yerly S, Combescure C, Auderset F, Desmeules J, et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis. 2015; https://doi.org/10.1016/S1473-3099(15)00154-1.
Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe — preliminary report. N Engl J Med. 2015; doi: 10.1056/NEJMoa1502924.
Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, et al. Articles efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein : interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2015;6736:1–10.
Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet. 2017; doi: 10.1016/S0140-6736(16)32621-6.
De Santis O, Audran R, Pothin E, Warpelin-Decrausaz L, Vallotton L, Wuerzner G, et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis. 2015; doi: 10.1016/S1473-3099(15)00486-7.
Tapia MD, Sow SO, Lyke KE, Haidara FC, Diallo F, Doumbia M, et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-bli. Lancet Infect Dis. 2015; doi: 10.1016/S1473-3099(15)00362-X.
Ebola Response Team WHO. Ebola virus disease among male and female persons in West Africa. N Engl J Med. 2016; doi: 10.1056/NEJMc1510305.
Maganga GD, Kapetshi J, Berthet N, Kebela Ilunga B, Kabange F, Mbala Kingebeni P, et al. Ebola virus disease in the Democratic Republic of Congo. N Engl J Med. 2014;371:2083–91.
Akerlund E, Prescott J, Tampellini L. Shedding of Ebola virus in an asymptomatic pregnant woman. N Engl J Med. 2015;372:2467–9.
Caluwaerts S, Lagrou D, Lledo P, Black B, Decroo T, Modet A, et al. Blood, birthing and body fluids : delivering and staying alive in an Ebola management Centre. 2015. https://www.msf.org.uk/sites/uk/files/3._28_caluwaerts_ebola_ocb_sv_final.pdf. Accessed 10 May 2017.
Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba N, et al. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med. 2014;371:1418–25.
Baggi FM, Taybi A, Kurth A, Van Herp M, Di Caro A, Wölfel R, et al. Management of pregnant women infected with Ebola virus in a treatment centre in Guinea, June 2014. Euro Surveill 2014; 19 (49): pii=20983.
Caluwaerts S, Fautsch T, Lagrou D, Moreau M, Camara AM, Günther S, et al. Dilemmas in managing pregnant women with ebola: 2 case reports. Clin Infect Dis. 2016;62:903–5.
Chertow DS, Kleine C, Edwards JK, Scaini R, Ruggero G, Sprecher A. Ebola virus disease in West Africa - clinical manifestations and management. N Engl J Med. 2014; doi: 10.1056/NEJMp1413084.
Caluwaerts S, Van Hern M, Cuesta JG, Crestani R, Ronsse A, Lagrou D, et al. Pregnancy and Ebola: management and survival of pregnant patients admitted to Médecins Sans Frontières Ebola treatment Centres in the 2014-2016 West Africa epidemic. In: Schwartz D, Anoko J, Abramowitz S, editors. Pregnant in the time of Ebola. Springer New York: Women and Their Children in the 2013–2015 West African Epidemic; 2017. p. [in press].
Schieffelin JS, Shaffer JG, Goba A, Gbakie M, Gire SK, Colubri A, et al. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med. 2014;371:2092–100.
Dörnemann J, Burzio C, Ronsse A, Sprecher A, De Clerck H, Van Herp M, et al. First newborn baby to receive experimental therapies survives Ebola virus disease. J Infect Dis. 2017;215:jiw493.
Oduyebo T, Pineda D, Lamin M, Leung A, Corbett C, Jamieson DJ. A pregnant patient with Ebola virus disease. Obstet Gynecol. 2015;126:1273–5.
Bower H, Grass JE, Veltus E, Brault A, Campbell S, Basile AJ, et al. Delivery of an ebola virus-positive stillborn infant in a rural community health center, Sierra Leone, 2015. Am J Trop Med Hyg. 2016;94:417–9.
Medicins Sans Frontières. NUBIA first newborn to survive Ebola. 2015. https://msf.exposure.co/nubia. Accessed 1 May 2017.
Vetter P, Kaiser L, Schibler M, Ciglenecki I, Bausch DG. Sequelae of Ebola virus disease: the emergency within the emergency. Lancet Infect Dis. 2016;16:e82–91.
Fowler R, Mishra S, Chan AK. The crucial importance of long-term follow-up for Ebola virus survivors. Lancet Infect Dis. 2016;16:987–9.
Deen GF, Knust B, Broutet N, Sesay FR, Formenty P, Ross C, et al. Ebola RNA persistence in semen of Ebola virus disease survivors — preliminary report. N Engl J Med. 2015; doi: 10.1056/NEJMoa1511410.
Sow MS, Etard J-F, Baize S, Magassouba N, Faye O, Msellati P, et al. New evidence of long-lasting persistence of Ebola virus genetic material in semen of survivors. J Infect Dis. 2016; doi: 10.1093/infdis/jiw078.
Mattia JG, Vandy MJ, Chang JC, Platt DE, Dierberg K, Bausch DG, et al. Early clinical sequelae of Ebola virus disease in Sierra Leone: a cross-sectional study. Lancet Infect Dis. 2015; doi: 10.1016/S1473-3099(15)00489-2.
Bausch DG, Towner JS, Dowell SF, Kaducu F, Lukwiya M, Sanchez A, et al. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis. 2007;196(Supp.2):S142–7.
Thorson A, Formenty P, Lofthouse C, Broutet N. Systematic review of the literature on viral persistence and sexual transmission from recovered Ebola survivors: evidence and recommendations. BMJ Open. 2016;6:e008859.
Howlett P, Brown C, Helderman T, Brooks T, Lisk D, Deen G, et al. Ebola virus disease complicated by late-onset encephalitis and polyarthritis, sierra leone. Emerg Infect Dis. 2016;22:150–2.
Fallah MP, Skrip LA, Dahn BT, Nyenswah TG, Flumo H, Glayweon M, et al. Pregnancy outcomes in Liberian women who conceived after recovery from Ebola virus disease. Lancet Glob Heal. 2016;4:e678–9.
WHO/International Study Team. Ebola haemorrhagic fever in Sudan, 1976. Bull World Health Organ. 1978;56:247–70.
Muehlenbachs A, de la Rosa VO, Bausch DG, Schafer IJ, Paddock CD, Nyakio JP, et al. Ebola virus disease in pregnancy: clinical, Histopathologic, and Immunohistochemical findings. J Infect Dis. 2016;215:64–9.
Kratz T, Roddy P, Oloma AT, Jeffs B, Ciruelo DP, De La Rosa O, et al. Ebola virus disease outbreak in Isiro, democratic Republic of the Congo, 2012: signs and symptoms, management and outcomes. PLoS One. 2015;10:1–18.
Ebola ca suffit ring vaccination trial consortium. The ring vaccination trial: a novel cluster randomised controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to Ebola. BMJ. 2015; doi: 10.1136/bmj.h3740.
Duraffour S, Malvy D, Sissoko D. How to treat Ebola virus infections? A lesson from the field. Curr Opin Virol. 2017;24:9–15.
Mentré F, Taburet A-M, Guedj J, Anglaret X, Keïta S, de Lamballerie X, et al. Dose regimen of favipiravir for Ebola virus disease. Lancet 2015; 15 February 150–151.
Bai CQ, Mu JS, Kargbo D, Bin SY, Niu WK, Nie WM, et al. Clinical and Virological characteristics of Ebola virus disease patients treated with Favipiravir (T-705) - Sierra Leone, 2014. Clin Infect Dis. 2016;63:1288–94.
Dunning J, Sahr F, Rojek A, Gannon F, Carson G, Idriss B, et al. Experimental treatment of Ebola virus disease with TKM-130803: a single-arm phase 2 clinical trial. PLoS Med. 2016;13:1–19.
PREVAIL II Writing Group, Multi-National PREVAIL II Study Team. A randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med. 2016;375:1448–56.
Edwards T, Semple MG, De Weggheleire A, Claeys Y, De Crop M, Menten J, et al. Design and analysis considerations in the Ebola_Tx trial evaluating convalescent plasma in the treatment of Ebola virus disease in Guinea during the 2014–2015 outbreak. Clin Trials. 2016; doi: 10.1177/1740774515621056.